Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25575137 | 1.00 | PEPD (0.50) | PEPDACEKDM4EHTTSMN1; SMN2 | |
| SCHEMBL25575140 | 1.00 | PEPD (0.50) | PEPDACEKDM4EHTTSMN1; SMN2 | |
| SCHEMBL26181646 | 1.00 | PEPD (0.50) | PEPDACEKDM4EHTTSMN1; SMN2 | |
| SCHEMBL25575142 | 0.95 | KDM4E (0.47) | PEPDKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL16141882 | 0.95 | KDM4E (0.47) | PEPDKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL26839145 | 0.95 | KDM4E (0.47) | PEPDKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL1115372 | 0.95 | KDM4E (0.47) | PEPDKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL18435274 | 0.95 | KDM4E (0.47) | PEPDKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL11400422 | 0.92 | KDM4E (0.46) | PEPDKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL28885167 | 0.92 | KDM4E (0.46) | PEPDKDM4EHTTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076131-A1 | DUAL PHOTO-SHADOW HYDROSILYLATION CURE AND SHADOW HYDROSILYLATION CURE SILICONE COMPOSITIONS FOR LIQUID OPTICALLY CLEAR ADHESIVE APPLICATIONS | Henkel IP & Holding GmbH (DE) | 2022-04-14 | — | — | WO | claimed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11649223-B2 | Amino compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230126447-A1 | OCULAR DRUG DEPOT FOR COMPLEMENT-MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| WO-2022076131-A1 | DUAL PHOTO-SHADOW HYDROSILYLATION CURE AND SHADOW HYDROSILYLATION CURE SILICONE COMPOSITIONS FOR LIQUID OPTICALLY CLEAR ADHESIVE APPLICATIONS | Henkel IP & Holding GmbH (DE) | 2022-04-14 | — | — | WO | disclosed |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180186782-A1 | AMIDE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| EP-0130633-B1 | Process for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoro propane derivatives | ZAMBON SPA (IT) | 1996-10-09 | — | — | EP | disclosed |
| EP-0678506-A2 | Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoro propane derivatives | ZAMBON GROUP S.p.A. (IT) | 1995-10-25 | — | — | EP | disclosed |
| EP-0677511-A2 | Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoro propane derivatives | ZAMBON GROUP S.p.A. (IT) | 1995-10-18 | — | — | EP | disclosed |
| US-5332835-A | Process for fluorinating 1-phenyl-2-amino-1,3-propanediol compounds and new oxazoline compounds useful in this process | ZAMBON S.P.A. (IT) | 1994-07-26 | — | — | US | disclosed |
| US-5243056-A | Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoro propane derivatives | ZAMBON S.P.A. (IT) | 1993-09-07 | — | — | US | disclosed |
| US-5153328-A | 2 Hydrocarbyl-4 substituted methyl 5 (4 substituted phenyl)-oxazolines | ZAMBON S.P.A. (IT) | 1992-10-06 | — | — | US | disclosed |
| US-5105009-A | Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoropropane derivatives | ZAMBON S.P.A. (IT) | 1992-04-14 | — | — | US | disclosed |
| WO-1989004334-A1 | CURABLE COMPOSITIONS CONTAINING ETHYLENICALLY UNSATURATED MONOMERS, POLYARYLCYANATE ESTER COMPOSITIONS AND CATALYST | THE DOW CHEMICAL COMPANY (US) | 1989-05-18 | — | — | WO | disclosed |
| US-4743700-A | Process for fluorinating 1-phenyl-2-amino-1,3-propanediol compounds | ZAMBON S.P.A. (IT) | 1988-05-10 | — | — | US | disclosed |
| EP-0130633-A2 | Process for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoro propane derivatives | ZAMBON GROUP S.p.A. (IT) | 1985-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186782-A1 | AMIDE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | PEPD 222/4885ACE 151/4885KDM4E 2775/4885 |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | PEPD 79/4885ACE 112/4885KDM4E 4286/4885 |
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | PEPD 222/4885ACE 151/4885KDM4E 2775/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | PEPD 84/4885ACE 167/4885KDM4E 3553/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | PEPD 84/4885ACE 167/4885KDM4E 3553/4885 |
| US-11649223-B2 | Amino compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | PEPD 62/4885ACE 137/4885KDM4E 3191/4885 |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | CFD, TFPI, CFH | PEPD 524/4885ACE 244/4885KDM4E 4269/4885 |
| US-20230126447-A1 | OCULAR DRUG DEPOT FOR COMPLEMENT-MEDIATED DISORDERS | CFD, CFB, CFH | PEPD 303/4885ACE 520/4885KDM4E 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.